Table 2

Participant demographics, current and prior treatment and experimental cohort

Participant number	Age (years)	Diagnosis	Disease duration (years)	DAS28 at baseline	Background DMARD treatment	Prior treatments	tolDC treatment
1	75	Seropositive RA	43	2.6*	PEN	Nil	1×10⁶
2	59	Seropositive RA	19	4.5	MTX s/c	SSZ, po MTX	Washout
3	53	Seropositive RA	14	6.0	ADA	PEN, gold, SSZ, MTX, LEF, ETA, ADA, RTX	1×10⁶
4	56	Psoriatic arthritis	6	2.6	MTX, LEF	Nil	1×10⁶
5	41	Undifferentiated seronegative arthritis	3	3.5*	MTX	SSZ	3×10⁶
6	63	Seropositive RA	31	5.1	MTX, ETA	MTX, LEF, gold, SSZ, PEN	Washout
7	35	Seropositive RA	3	4.4	MTX, SSZ, HCQ	Nil	3×10⁶
8†	47	Seronegative arthritis	1	1.4	MTX	SSZ	3×10⁶†
9	60	Seronegative RA	14	5.2	MTX, HCQ	Nil	3×10⁶
10	77	Psoriatic arthritis	3	4.4*	MTX, SSZ	Nil	10×10⁶
11	65	Seropositive RA	2	4.5	MTX, SSZ, HCQ	Nil	Washout
12	57	Undifferentiated seronegative arthritis	4	2.3	MTX	Nil	10×10⁶
13	45	Psoriatic arthritis	18	2.2	Nil	MTX, SSZ	10×10⁶

*Screening DAS28 values.
†Cells failed release criteria.
ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PEN, penicillamine; po, oral administration; RA, rheumatoid arthritis; RTX, rituximab; s/c, subcutaneous administration; SSZ, sulfasalazine; tolDC, tolerogenic dendritic cells.